Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology

Histology and Histopathology

Volumn 16, Issue 1, 2001, Pages 269-275

  Prendergast, G C ^a  

^a DuPont Pharmaceuticals Company   (United States)

Author keywords

Cancer; Experimental therapeutics; Malignant transformation; Ras; Signal transduction

Indexed keywords

CISPLATIN; CYTOKINE RECEPTOR; GEMCITABINE; INTEGRIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CELL FUNCTION; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOSKELETON; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; NEUTROPENIA; NONHUMAN; ONCOGENE RAS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; NEOPLASMS; RHOB GTP-BINDING PROTEIN;

EID: 0035151646     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Intracellular localization of the p21rho proteins
2. Gene trapping identifies inhibitors of oncogenic transformation: The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I-alpha-2 (COL1A2) are epidermal growth factor-regulated growth repressors
3. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2
4. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis
5. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
6. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
7. Protein prenyltransferases
8. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS
9. Farnesyltransferase inhibitors and cancer treatment: Targeting simply Ras?
10. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation
11. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors
12. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors
13. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
14. Elevation of α2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors
15. Activation of the IGF-PI3′K pathway masks the proapoptotic effects of farnesyltransferase inhibitors
16. RhoB encoding a UV-inducible ras-related small GTP-binding protein is regulated by GTPases of the rho family and independent of JNK, ERK, and p38 MAP kinase
17. Rho GTPases are overexpressed in human tumors
18. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments
19. Regulation of epidermal growth factor receptor traffic by the small GTPase RhoB
20. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
21. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
22. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells
23. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells
24. Orthotopic models are necessary to predict therapy of transplantable tumors in mice
25. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
26. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
27. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
28. Functional interaction between RhoB and the transcription factor DB1
29. Non-Ras targets for farnesyltransferase inhibitors: Focus on Rho
30. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity
31. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
32. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment
33. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase-I inhibitor in human tumor cell lines
34. RhoB alteration is required for the apoptotic and antineoplastic effects of farnesyltransferase inhibitors
35. Antitumor activity of SCH 6636, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
36. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
37. PRK1 is targeted to endosomes by the small GTPase, RhoB
38. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
39. Effect of farnesyltransferase overexpression on cell growth and transformation
40. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956
41. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
42. Farnesyltransferase inhibitors: Targeting the molecular basis of cancer
43. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton
44. Critical role of Rho in cell transformation by oncogenic ras
45. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors
46. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
47. Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells
48. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin taxol, and gemcitabine
49. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells
50. Suppression of tumorigenicity in Ras-transformed fibroblasts by alpha 2(1) collagen
51. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs
52. K- and N-ras geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
53. Regulation of Ras-related RhoB protein expression during the cell cycle
54. Protein prenylation: Molecular mechanisms and functional consequences